ALPEGA-GROUP
Alpega, a global leader in logistics SaaS software, announces its recognition as a Challenger in the 2024 Gartner Magic Quadrant for Transportation Management Systems (TMS). We believe this acknowledgment underscores Alpega’s unwavering commitment to delivering cutting-edge solutions tailored to meet the evolving demands of the transportation industry. The Gartner report evaluates vendors based on their completeness of vision and ability to execute.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417652913/en/
(Photo: Alpega)
Alpega serves global customers with deployments in all geographies, addressing diverse sectors such as automotive, retail, fast-moving consumer goods, and manufacturing, Alpega places significant emphasis on fostering collaboration with carriers, optimizing transportation procurement, and championing environmental, social, and governance (ESG) initiatives.
Backed by a history of exceptional customer retention rates and proactive engagement, Alpega pledges unparalleled support and satisfaction. As the company continues to expand its business, it remains steadfast in its commitment to deliver creative solutions to the problems remaining in the transportation space, solidifying its status as a trusted partner in the ever-evolving domain of logistics. We invite you to learn more about our recognition by accessing the complete Gartner Magic Quadrant report [here].
Alpega CEO, Todd DeLaughter, remarked, “As we celebrate our recognition as a Challenger in the 2024 Gartner Magic Quadrant, we reaffirm our commitment to pushing the boundaries of innovation and excellence in transportation management technology. With a customer-centric ethos and an unyielding drive for progress, we are poised to lead the industry towards a future defined by efficiency, sustainability, unparalleled service and most importantly, unlocking business value for our customers.”
Gartner subscribers can access the complete Magic Quadrant for Transportation Management Systems here Gartner Disclaimer.
Recognized as Alpega Group from 2020 to 2024 and as inet-logistics from 2011 to 2019.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Alpega
Alpega is a leading global logistics SaaS software company committed to providing comprehensive end-to-end solutions that cater to all transport requirements. Our overarching mission is to enable shippers and carriers to navigate today's logistics challenges efficiently through digitalization, thereby driving smarter logistics for a greener tomorrow
Harnessing the extensive assets of our carrier network, Alpega delivers tangible benefits across Execution, Planning, Sourcing, and Payment solutions. As the premier SaaS provider offering Transport Management Systems (TMS) for shippers, alongside an 80,000-strong open carrier network covering approximately 10% of all commercial trucks in Europe, we stand at the forefront of innovation and efficiency. For carriers, our connectivity spans three premier freight exchanges in Europe, with notable leadership in Iberia, Romania, Central, and South-eastern European regions, facilitating seamless matching of freight loads with transportation capacity.
With over three decades of transportation expertise, we empower businesses to streamline their supply chain planning and execution, resulting in reduced costs and enhanced visibility. Alpega's suite of solutions synergistically creates added value for our customers. Our community comprises 80,000 carriers and 200,000 members, electronically interconnected each day to efficiently manage vital transport operations. Operating in 80 countries worldwide, Alpega boasts a diverse team of over 500 professionals representing 31 nationalities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417652913/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom